Orally active, potent γ-secretase inhibitor (IC50 = 12 nM). Inhibits Aβ40 and Aβ42 formation in vitro (IC50 values are 7.4 and 7.9 nM respectively) and reduces Aβ in the brain, plasma and cerebrospinal fluid in vivo. Exhibits no Notch toxicity. Brain penetrant.
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 511.94. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.95 mL||9.77 mL||19.53 mL|
|5 mM||0.39 mL||1.95 mL||3.91 mL|
|10 mM||0.2 mL||0.98 mL||1.95 mL|
|50 mM||0.04 mL||0.2 mL||0.39 mL|
References are publications that support the products' biological activity.
Barten et al (2005) Dynamics of β-Amyloid reductions in brain, cerebrospinal fluid, and plasma of β-amyloid precursor protein transgenic mice treated with a γ-secretase inhibitor. J.Pharmacol.Exp.Ther. 312 635 PMID: 15452193
Anderson et al (2005) Reductions in β-amyloid concentrations in vivo by the γ-secretase inhibitors BMS-289948 and BMS-299897. Biochem.Pharmacol. 69 689 PMID: 15670587
Goldstein et al (2007) Ex vivo occupancy of the γ-secretase inhibitors correlates with brain β-amyloid peptide reduction in Tg2576 mice. J.Pharmacol.Exp.Ther. 323 102 PMID: 17640949
If you know of a relevant reference for BMS 299897, please let us know.
View Related Products by Product Action
Keywords: BMS 299897, supplier, BMS299897, gamma-secretase, inhibits, orally, active, inhibitors, g-secretase, beta-amyloid, b-amyloid, γ-secretase, β-amyloid, amyloidbeta, amyloidb, amyloidβ, Gamma-Secretase, Amyloid, Beta, Peptides, Gamma-Secretase, Tocris Bioscience
Citations for BMS 299897
Citations are publications that use Tocris products.
Currently there are no citations for BMS 299897. Do you know of a great paper that uses BMS 299897 from Tocris? If so please let us know.
Reviews for BMS 299897
There are currently no reviews for this product. Be the first to review BMS 299897 and earn rewards!
Have you used BMS 299897?
Submit a review and receive an Amazon gift card.
$10US/$10CAN/€7/£6 gift card for a review without an image
$25US/$25CAN/€18/£15 gift card for a review with an image
*Offer only valid in the USA / Canada, UK and EuropeSubmit a Review
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.